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EVALUATION OF GLYCOPROTEIN B GENOTYPES AND LOAD OF CMV INFECTING BLOOD 
LEUKOCYTES ON PROGNOSIS OF AIDS PATIENTS
Aldo Albuquerque CUNHA(1), Vitor Hugo AQUINO(1), Viviane MARIGUELA(1), Maurício Lacerda NOGUEIRA(2)& Luiz Tadeu Moraes FIGUEIREDO(1)
SUMMARY
Background: Cytomegalovirus (CMV) remains an important pathogen to immunocompromised patients even in the era of HAART. 
The present study aimed at evaluating the influence of CMV viral load and its gB genotypes on AIDS patients’ outcome. Methods: 
Blood samples of 101 AIDS patients were collected and tested for HIV load, CD4 - cell count and opportunistic pathogens, including 
CMV. Semi nested PCRs were run to detect CMV genome and in the positive samples, gB genotyping and CMV load were established 
using enzymatic restriction and real time PCR, respectively. All patients were clinically followed for four years. Results: In thirty 
patients (31%) CMV was detected and all fatal cases (n = 5) occurred in this group of patients (p = 0.007), but only two patients had 
CMV disease (1.9%). However, viral load was not statistically associated with any analyzed parameter. The most frequently observed 
CMV genotype was gB2 (45.16%) followed by gB3 (35.48%). gB2 genotype was more frequently found in patients with CD4- cell 
counts under 200 cells/mm3 (p = 0.0017), and almost all fatal cases (80%) had gB2 genotype. Conclusions: Our study suggests that 
CMV and its polymorphisms in biologically relevant genes, such as the gB encoding ORF, may still influence the prognosis and 
outcome of AIDS patients. The gB2 genotype was associated to patient’s bad outcome.
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INTRODUCTION
Cytomegalovirus (CMV) is a ubiquitous herpesvirus that is 
the causative of asymptomatic or mild symptomatic infections in 
immunocompetent hosts25. Conversely, in immunocompromised patients, 
such as those with AIDS or in transplant recipients, CMV might produce 
significant morbidity and mortality2,17.
CMV glycoprotein B (gB) is a highly immunogenic protein 
incorporated into the viral envelope, which is believed to exert an 
essential biological role in virus host interaction, since it participates 
in the entry, propagation and replication of the virus in different host 
cells3,18. Wild type CMV strains can be classified into four major gB 
genotypic variants (gB 1- 4) based on gB sequence. Each of them have 
tropism for distinct cell lines, leading to different pathogenesis and 
severity of disease6,20,23,27. Thus, the genotypic characterization of CMV 
strains infecting immunocompromised individuals can contribute to 
epidemiological molecular studies and to the definition of the role of 
viral genetic variability in clinical expression and prognosis. Besides 
this, CMV infection might reduce patient’s immune response, favoring 
the onset of opportunistic diseases and in some cases, death24.
Several studies have tried to correlate the infection by different gB 
genotypes of CMV with clinical prognosis of individuals4,5,27,28. Therefore, 
the aims of the present study were to determine the incidence of CMV 
infecting blood leukocytes of HIV-infected individuals in a Brazilian care 
unit, the incidence of gB genotypes and loads of their infective CMV 
strains, and correlate this information with laboratorial and clinical data 
obtained during a 4-year follow -up.
PATIENTS AND METHODS
One hundred one AIDS patients at different phases of the disease 
and followed at the General Hospital of the School of Medicine of 
Ribeirão Preto/University of São Paulo (HCFMRP/USP) and at the 
county ambulatories of Jaboticabal and Monte Alto (São Paulo State, 
Brazil), were invited to participate in this study. This protocol was 
approved by the Ethics Review Board of HCFMRP -USP (process # 
1976/2002).
Blood samples were collected from 2001 to 2002 and all participants 
attended follow-up visits every three months during four years. The 
following clinical data were registered during their visits: gender, age, 
stage of HIV infection, occurrence of opportunistic infections including 
those caused by CMV, and information on the intake of highly active 
antiretroviral therapy (HAART). T -CD4 cell counts and HIV loads by 
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the time of first sampling and in the last clinical visit were included in 
the study as laboratorial parameters of patient development. 
DNA extraction and nested-PCR for detection of CMV 
genome: For PCR test, the blood samples (5 mL), collected 
in EDTA- containing tubes, leukocytes were separated with the 
addition of 1% dextran solution and the DNA of the cells from the 
buffy coat were extracted by the phenol- chlorophorm method16. To 
amplify CMV DNA we used a nested-PCR technique previously 
reported by CUNHA et al.7. The PCR was performed using CMV 
primers as follows: gB 1319 (5’- TGGAACTGGAACGTTTGGC3’) 
and gB 1604 (5’GAAACGCGCGGCAATCGG-3’) as external 
primers. In the second round a nested PCR was performed using 
gB 1319 (5’- TGGAACTGGAACGTTTGGC3’) and gB 1676 
(5’TGACGCTGGTTTGGTTGAATG3’) as external primer. The reaction 
mixture of the PCR contained in a total volume of 50 µL, 75 mM of Tris 
HCl (pH 9), 2 mM of MgCl2, 50 mM of KCl, 20 mM of (NH4)2SO4, 50 µM 
of each one of the deoxynucleoside triphosphates, 0.3 µM of primers 
gB1319 and gB1604, and one µg of DNA obtained from primary blood 
lymphocytes. The reaction mixture was first incubated at 94 °C for three 
min. Next, the temperature was reduced to 80 °C, when 2 U of Taq DNA 
polymerase were added and the mixture was submitted to 15 cycles of 
60 sec at 94 °C, 120 sec at 65 °C, and 120 sec at 72 °C, and to 30 cycles 
of 60 sec at 94 °C, 90 sec at 55 °C, 120 sec at 72 °C, and finally to three 
min at 72 °C. Two microliters of these reaction products were used in 
the nested- PCR, included in a reaction mixture similar to that mentioned 
above, except for the primers gB1319 and gB1604. PCR and nested -PCR 
products were subjected to electrophoresis in a 2% agarose gel and the 
amplicon bands were visualized under UV light after ethidium bromide 
staining. A 100 base pair (bp) marker (Amersham Pharmacia, USA) was 
used to estimate the size of bands. Amplicons from nested -PCR were 
further used for genotyping CMV.
CMV load by real time PCR: In DNA extracts of leukocytes in 
which CMV was detected by nested-PCR, the CMV load was also 
determined by real time PCR. The reaction was carried out using 
a 40 -cycle TaqMan PCR assay. The reaction mixture, containing 
primers and probe designed in our laboratory from the region 
of gB- CMV, included 10 picomols/10 ηl of the forward primer 
(5’- TGGAATCGGTGCACAATCTG- 3’) and 10 picomols/10 ηl of the 
reverse primer (5’- CGCGCAACGTGTCATAGG -3’) in a volume of 
1 µL, five picomols/10 ηl of a probe (6FAMACGCCCAGCTGCAGTT 
MGBNFQ) in a volume of one µL, master -mix (2x concentrated) buffer 
containing TaqMan in a volume of five µL, plasmid or clinical sample 
DNAs in a volume of one µL of DEPC treated water, in a final volume of 
10 µL. The reaction was carried out in a RT- PCR 7500 device (Applied 
Biosystems, USA), and was monitored from 700 to 770 nm. To avoid 
false positive results, specimens were processed in parallel with negative-
control aliquots of phosphate buffered saline. PCR were run in triplicate 
and the final CMV load was considered as the mean of the three values.
CMV genotyping: The amplicons of CMV obtained by nested-
PCR were submitted to an enzymatic cleavage for gB genotyping. In 
this case, 10 µL of a mixture containing the amplicons were added to a 
microtube containing two uL of the proper buffer solution. The enzymes 
HinfI or RsaI (New England Biolabs, USA) (10 U, from each enzyme) 
were added to the solution, the volume being 20 µL. After one hour 
incubation at 37 °C, the digested products were visualized in a 1% agar 
gel, after electrophoresis at 100V, for 45 min. This procedure allowed 
discrimination of fragments with similar weights (up to 10 bp), and thus 
the identification of the four described gB genotypes6.
Statistical analysis: The model of logistic regression was used to 
verify the influence of CMV viral load over T- CD4 counts, HIV viral load, 
medication intake and incidence of death and opportunistic infections. 
The unpaired Student´s t -test was used for analysis of parametric data, 
such as time of diagnosis and age from CMV positive and negative 
individuals. 
To analyze differences in CMV viral loads and T- CD4 counts among 
groups of samples with different CMV genotypes, Kruskal -Wallis non-
parametric test was used and in case of significance, the post- test of 
multiple comparisons10 was performed.
RESULTS
CMV detection by semi -nested- PCR: Analyzing leukocyte samples 
from 101 AIDS patients CMV genome was detected in 31 (31%). In 
these patients, CMV was detected at different times during follow-up. 
Baseline information on patients with positive and negative samples for 
CMV is shown in Table 1. In the group of patients with CMV positive 
samples, 30 to 35 year-old females predominated, while in the CMV 
negative group 35 to 40 year-old males predominated (p 0.05353, for 
gender and p 0.6, for age). The time since AIDS was diagnosed did not 
differ for both groups (p 0.141).
Table 1









Age (Mean ± SE) 37.64 ± 1.190 38.77 ± 1.797; p = 0.60
Current HIV treatment
None1 20% 23%
3 ARVs 60% 71% 
Booster 20% 6%
Use of ARVs2
Regular use 44% 46% 
Irregular use 56% 54%
T- CD4 counts, cells/mL 
(Mean ± SE)
426.1 ± 32.49 290.6 ± 47.15*; p = 0.02
Time (yrs) since HIV 
diagnosis (Mean ± SE)
5.66 ± 1.93 5.00 ± 1.77; p = 0.141
1Patients in this group either abandoned medication, had it suspended for any reason 
or did not start the medication. 2Data from this item correspond to what is declared 
by patients. *Data compared using non- paired t- test, 95% confidence interval.
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At the end of the follow-up, most of the patients with detected CMV 
were also symptomatic for HIV- related infections (53%). Among then, 
toxoplasmosis was the opportunistic infection most frequently detected 
(12%). The group of participants without CMV infection of leukocytes 
was mostly asymptomatic (70%) and tuberculosis was the most frequent 
opportunistic infection (14%). Moreover, in the majority of patients at 
C3 AIDS stage CMV was detected in leukocytes (p 0.0064) (Table 2). 
Also, five of the patients died during this period (Table 3). 
During follow-up the CD4 -cell counts increased in values for the 
majority of the enrolled patients, and the HIV loads remained stable 
throughout the study period; in spite of most participants making irregular 
use of HAART. 
Regarding CMV disease, only two patients in the CMV positive 
group had diagnosis of encephalitis and esophagitis (6%, p 0.1005, OR 
0.08936) by this virus. However, 16% of the patients with CMV detected 
in the leukocytes died during the follow-up while no deaths occurred 
among those uninfected by CMV (p 0.0021).
CMV viral load: The real time PCR was able to detect one copy of the 
plasmid containing part of the gB gene of CMV. Therefore, CMV load of 
the participants ranged from 100 to 35,000 viral copies/1.5x105 leukocytes. 
Considering as high CMV load values above 200 viral copies/1.5 x 105 
leukocytes, two groups of CMV -AIDS patients were created, including 
those with < 200 and > 200 CMV copies/1.5 x 105 leukocytes. No 
association was observed for the values of CMV and HIV viral loads (p 
= 0.6144) and neither for CMV loads and T- CD4 cell counts (p 0.3947) 
(Table 4). However, three out five fatal cases had > 200 viral copies of 
CMV/1.5 x 105 leukocytes and also T- CD4 cell counts under 55 cells/mL.
A number higher than 200 viral copies of CMV/1.5 x 105 leukocytes 
had 60% sensitivity, 34% specificity, 15% predictive positive value and 
82% predictive negative value for prediction of bad prognosis of AIDS. 
gB genotypes of CMV: All 4 gB genotypes of CMV were observed 
in the leukocytes of the AIDS patients and frequency distribution of 
genotypes was 45.16%, in 35.48%, 12.9% and 6% for gB2, gB3, gB4 
and gB1, respectively.
Table 5 shows median values of CD4 -cell counts and CMV viral 
loads among samples having different gB genotypes. Although most 
individuals infected with gB2 genotype had CMV loads higher than 200 
viral copies/1.5 x 105 leukocytes, no statistical difference was observed 
for mean CMV loads (p 0.11). However, most patients infected with 
gB2 strain had T- CD4 counts below 200 cells/mL (p 0.0017). Also, 
gB2 genotype was present in leukocytes of 80% (4/5) of the fatal cases. 
Conversely, the frequency of gB3 genotype was higher among individuals 
with CMV loads < 200 viral copies/1.5 x 105 leukocytes.
The presence of gB2 genotype of CMV infecting leukocytes as a 
predictor of bad prognosis for AIDS showed 80% sensitivity, 61.5% 
specificity, 28% positive predictive value and 94% negative predictive 
value.
DISCUSSION
This 4 -year follow-up work focused on the effects of CMV infection 
in AIDS patients, analyzing the association of CMV load and gB 
Table 2











CMV Encephalitis 0% 3%
Other opportunist infection  10% 9%
Deaths 0% 12%
Table 3
Key findings from patients that came to death during the follow- up
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
CD4- cell count 38 35 53 41 6
CMV viral load 117 16900 758 120 707
HIV viral load 67170 230000 256247 71556 16761
CMV genotype gB3 gB2 gB2 gB2 gB2
Opportunistic infection Neurocripto Pneumocystosis Cryptococcosis Neurotoxoplasmosis
Years from AIDS diagnosis 3 5 2 >5 3
Medication intake NA Irregular Irregular Irregular Regular
HAART regimen NA Biovir+EFV Biovir+EFV Biovir+EFV Biovir+EFV
NA – Not applicable.
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genotypes as parameters of disease development and prognosis. This 
information was obtained by molecular biology techniques such as 
PCR, which are widely considered as suitable tools. The drawback of 
this technique is the high sensitivity, which raised concern regarding 
the diagnosis of the pathogen effectively causative of patient’s clinical 
symptoms. Previously, we have used PCR for CMV genome detection in 
samples of children and patients with kidney transplant, obtaining specific 
and reproducible results1,7,29, although with a highly sensitive method, 
we could be detecting latent CMV incorporated into leukocytes DNA19. 
Thus, to improve the diagnosis of CMV disease, a real time PCR virus 
quantification method was used trying to establish a clinically relevant 
cut- off value for CMV viral load in leukocytes.
Our data point to a high prevalence of CMV (31%) among AIDS 
patients when compared to that observed by DEYTON et al.8. These 
authors looked for CMV genome by PCR in blood samples of a group 
of 374 patients during a follow-up study of 37 months. According to 
these authors, in the initial test, CMV genome was detected in 15.8% 
of samples (59 patients). Although the rate of positive samples was not 
stable throughout the above follow-up study, the difference in values of 
initially positive samples with the present study could be explained by 
the high prevalence of CMV infection in Brazil, about 95%7,29.
Considering the baseline population characteristics, our results are 
similar to those reported by a multicentre study conducted by JABS et 
al.15, except for the high prevalence of females in the CMV detected 
group. Moreover, similar to our data, most patients in this previous 
report were using HAART. Interestingly, our results demonstrate that a 
large proportion of patients had referred to an irregular use of HAART 
during the follow-up period, although there was no increase of their HIV 
loads, indicating that even used irregularly, HAART may decrease HIV 
replication and thus allow the rescue of immune function. 
The issue of whether CMV remains as a risk factor for patients 
receiving HAART has been reviewed elsewhere14,26. Both works came 
to the conclusion that HAART reduced the incidence of CMV disease 
among patients, although CMV remains a risk factor for prognosis of 
AIDS patients with CD4 -cell counts below 100 cells/mm3. Our results 
showed that the presence of CMV in blood leukocytes was associated 
with case fatality and in all death cases patients had CD4 below 
55 cell/mm3, indicating that they were severely immune depressed. 
Probably, as a consequence, these patients had high CMV loads, which 
could also contribute to disease progression. None of the fatal cases 
had symptoms of CMV disease, suggesting that CMV itself was not the 
direct cause of death of these patients. In this regard, SPENCER et al.24 
suggested that CMV indirectly contributes to immune depression of AIDS 
patients. These authors related the presence of an interleukine- 10-like 
protein that is expressed during CMV infection. This protein suppresses 
Th1 immune response, acting synergistically with HIV aggravating 
immune system depression.
Considering CMV loads, our real time PCR was highly sensitive 
being able to detect one copy of plasmid per µL, similar to that reported by 
SANCHEZ & STORCH22 using the same technique. Therefore, the values 
for CMV viral loads ranged from 100 to 35,000 viral copies/1.5x105 
leukocytes with the majority of patients presenting > 200 viral copies/1.5 
x 105 leukocytes. GOURLAIN et al.13 reported that six out of 16 patients 
with CMV loads higher than 100 viral copies/1.5 x 105 leukocytes 
(detected by RT -PCR) developed CMV disease. Plasma samples from 
these patients had CD4+- cell counts below 75 cells/mm3 and HIV loads 
higher than 100,000 viral copies/mL which was also predictive of CMV 
disease. In our work, CMV viral loads were not correlated with CD4 
counts, HIV loads or incidence of death, although high CMV viral loads 
were observed in one fatal case. Also, our data points to a low incidence 
of CMV disease, two out of 31 patients with CMV genome detected 
had CMV disease based on suggestive clinical presentation of CMV 
encephalitis and esophagitis. In both cases, viral loads were higher than 
200 viral copies/1.5 x 105 leukocytes.
Considerable attention has been paid to the glycoprotein B from CMV 
viral envelope and many studies have tried to establish the influence of 
different gB genotypes (gB1 -4) on the patient’s outcome [for review see 
Table 5
Values of CD4- cell counts and CMV viral loads in samples of patients with 
different gB genotypes
Genotype Variable Median Min value Max value
gB1 CD4 487 449 525
CMV 1615 660 2570
gB2 CD4 99.5 6 334
CMV 1560** 120 32300
gB3 CD4 341 38 1149
CMV 125 100 3380
gB4 CD4 510 492 548
CMV 289 100 2400
Data from 31 patients with CMV detected genome by PCR. Analyses were per-
formed using Kruskal -Wallis test for CD4- cell counts (cell/mm3) and viral loads 
(viral copies/1.5 x 105 leukocytes).  Dunn’s test was used as post test.  ** p < 0.001.
Table 4
Frequencies of individuals in two ranges of values for CMV viral loads and 
different T- CD4 cell counts
CMV load p-value 
Odds Ratio<200 >200
T- CD4 cell counts 0.7284a
0-200 4 11 1.173(0.477;2.880)
200-500 3 6
>500 1 6 0.3947b
1.732(0.489;6.137) 
HIV viral load
<10000 copies 3 5 0.6144
>10000 copies 11 12 1.528(0.294;7.944)
Data in this table is represented by number of patients.  Statistical analysis used 
logistic regression model with 95% confidence interval. (a) p- values and odds 
ratio for the influence of CMV loads on T- CD4 counts from 0- 200 and 200- 500. 
(b) p- values and odds ratio for the influence of CMV loads on T -CD4 counts 
from 200- 500 and >500.
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26]. However, the correlation of gB genotypes and disease progression 
is still unclear. The distribution frequencies of gB genotypes may vary 
according to groups of immunocompromised patients. In bone marrow 
transplant recipients and AIDS patients, gB2 and 3 are more often found, 
while in congenitally infected babies gB1 is more frequent3. Our findings 
indicate that gB2 genotype was most encountered (45.16%) in samples 
of AIDS patients with CD4- cell counts below 200 cells/mm3, although 
CMV disease was rarely observed. Also, patients with gB2 strains had 
CMV loads higher than 200 copies/1.5x105 leukocytes, but again no 
association between genotype and viral load was observed. Besides, 
it was observed in another study that neutralizing an antibody to gB2 
human cytomegalovirus does not prevent reactivation in patients with 
human immunodeficiency virus infection21.
Interestingly, in our work, 80% (4/5) of patients that died were infected 
with gB2 CMV genotype, which could be due either to the high prevalence 
of this genotype or to a real association of gB2 and immune suppression. 
In a previous study, GILBERT et al.11 observed a similar predominance 
of gB2 genotype patients with low CD4 -cell counts in AIDS patients with 
and without CMV retinitis, indicating no association between genotype 
and disease. DREW et al., in 2002, found that half of AIDS patients had 
gB2 genotype and that this genotype is not a major determinant of retinitis 
pathogenicity but appears to be highly prevalent among HIV-infected 
patients9. In the Netherlands, differently, however, it was found that CMV 
gB3 was the most prevalent gB genotype in AIDS patients, but also double 
or triple infection with other CMV gB strains were common12. Nevertheless, 
the confirmation of the virulence of gB2 genotype observed in the present 
study must be assessed in a larger casuistic study. 
CONCLUSIONS
Cytomegalovirus infection remains as a risk factor for 
immunocompromised individuals, even in the HAART era. Although 
the presence of CMV genome was not associated with the incidence 
of CMV disease, a relevant proportion of patients co infected with HIV 
and CMV died (12%), while CMV genome was detected mostly in 
individuals with CD4- cell counts lower than 100 cells/mm3. Moreover, 
our results may raise the issue of whether the presence of CMV gB2 
genotype could be a predictor of bad prognosis and decrease of immune 
response, even in patients using HAART. In the light of these facts, an 
integration of clinical and virological data may favor the evaluation of 
prognosis of AIDS patients.
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RESUMO
Avaliação de genótipos de glicoproteína B e carga de CMV de 
leucócitos no prognóstico de pacientes de Aids
Antecedentes: O citomegalovírus (CMV) permanece um importante 
patógeno para pacientes imunocomprometidos, mesmo na era da 
HAART. O presente estudo teve como objetivo avaliar a influência da 
carga viral do CMV e seu genótipo gB sobre a evolução de pacientes 
com AIDS. Métodos: Amostras de sangue de 101 pacientes com AIDS 
foram coletadas e testadas para carga viral de HIV, a contagem de células 
CD4 e patógenos oportunistas, incluindo o CMV. Um sistema de PCRs 
seminested foi utilizado para detectar o genoma do CMV e em amostras 
positivas a carga viral de CMV e genotipagem foram estabelecidos por 
restrição enzimática e PCR em tempo real, respectivamente. Todos 
os pacientes foram acompanhados clinicamente durante quatro anos. 
Resultados: Trinta pacientes (31%) tiveram CMV detectado e todos os 
casos fatais (n = 5) ocorreram em pacientes deste grupo (p = 0,007), porém 
apenas dois pacientes tinham doença por CMV (1,9%). No entanto, a 
carga viral não foi associada estatisticamente a nenhum dos parâmetros 
analisados. O genótipo de CMV mais freqüentemente observado foi gB2 
(45,16%), seguido por gB3 (35,48%). O genótipo gB2 foi mais freqüente 
em pacientes com contagens abaixo de 200 células/mm3 CD4cell (p = 
0,0017), e quase todos os casos fatais (80%) tinham o genótipo gB2. 
Conclusão: Nosso estudo sugere que CMV e seu polimorfismo em 
genes relevantes biologicamentes, como a gB, pode ainda influenciar 
no prognóstico e evolução de pacientes com AIDS. O genótipo gB2 foi 
associado ao mau prognóstico do paciente.
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